Literature DB >> 28192715

Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease.

I Theberge1, J Bowdridge2, M A Forgie2, M Carrier2, M Louzada2, L Siquiera2, M Rhodes2, P S Wells3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28192715     DOI： 10.1016/j.thromres.2017.02.003

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  3 in total

Review 1.  Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.

Authors:  A Franco-Moreno; L Cabezón-Gutiérrez; M Palka-Kotlowsa; M Villamayor-Delgado; M García-Navarro
Journal:  J Thromb Thrombolysis       Date:  2019-04       Impact factor: 2.300

2.  Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.

Authors:  Olivia S Costa; Christine G Kohn; Nicole M Kuderer; Gary H Lyman; Thomas J Bunz; Craig I Coleman
Journal:  Blood Adv       Date:  2020-09-08

Review 3.  Managing thrombosis in cancer patients.

Authors:  Tzu-Fei Wang; Ang Li; David Garcia
Journal:  Res Pract Thromb Haemost       Date:  2018-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.